keyword
MENU ▼
Read by QxMD icon Read
search

Cooper PS

keyword
https://www.readbyqxmd.com/read/28405166/egfr-mutation-in-squamous-cell-carcinoma-of-the-lung-does-it-carry-the-same-connotation-as-in-adenocarcinomas
#1
Amit Joshi, Saurabh Zanwar, Vanita Noronha, Vijay M Patil, Anuradha Chougule, Rajiv Kumar, Amit Janu, Abhishek Mahajan, Akhil Kapoor, Kumar Prabhash
BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the outcomes of EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR mutation in metastatic squamous cell carcinoma (SCC) of the lung has been debated. METHODS: All patients with metastatic SCC who underwent EGFR mutation testing at our center from 2010 to 2015 were included for analysis. EGFR kinase domain mutations were tested using Taqman-based real-time polymerase chain reaction (PCR)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28403082/metronomic-oral-cyclosphosphamide-as-third-line-systemic-treatment-or-beyond-in-patients-with-inoperable-locoregionally-advanced-recurrent-or-metastatic-nasopharyngeal-carcinoma
#2
Victor H F Lee, Dora L W Kwong, Ka-On Lam, Yu-Ching Lai, Yun Li, Chi-Chung Tong, Patty P Y Ho, Wing-Lok Chan, Lai-San Wong, Dennis K C Leung, Sum-Yin Chan, Fong-Ting Chan, To-Wai Leung, Anne W M Lee
There is no standard third-line or further systemic treatment for patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). Metronomic oral cyclophosphamide provides an acceptable and cheap option for these heavily pretreated patients who had limited choices. We conducted a prospective phase II single-arm open-label study of metronomic oral cyclophosphamide. Patients with locoregionally advanced recurrent inoperable (rT3/T4, rN2-N3b) or metastatic (rM1) NPC who had Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0-2) and had progressed after at least 2 lines of palliative systemic chemotherapy were eligible...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28388167/collective-hydration-dynamics-in-some-amino-acid-solutions-a-combined-ghz-thz-spectroscopic-study
#3
Nirnay Samanta, Debasish Das Mahanta, Samiran Choudhury, Anjan Barman, Rajib Kumar Mitra
A detailed understanding of hydration of amino acids, the building units of protein, is a key step to realize the overall solvation processes in proteins. In the present contribution, we have made a combined GHz (0.2-50) to THz (0.3-2.0) experimental spectroscopic study to investigate the dynamics of water at room temperature in the presence of different amino acids (glycine, L-serine, L-lysine, L-tryptophan, L-arginine, and L-aspartic acid). The THz absorption coefficient, α(ν), of amino acids follows a trend defined by their solvent accessible surface area...
March 28, 2017: Journal of Chemical Physics
https://www.readbyqxmd.com/read/28379811/predictors-of-delirium-in-corticosteroid-treated-patients-with-advanced-cancer-an-exploratory-multicenter-prospective-observational-study
#4
Naoki Matsuo, Tatsuya Morita, Yoshinobu Matsuda, Kenichiro Okamoto, Yoshihisa Matsumoto, Keisuke Kaneishi, Takuya Odagiri, Hiroki Sakurai, Hideki Katayama, Ichiro Mori, Hirohide Yamada, Hiroaki Watanabe, Taro Yokoyama, Takashi Yamaguchi, Tomohiro Nishi, Akemi Shirado, Shuji Hiramoto, Toshio Watanabe, Hiroyuki Kohara, Satofumi Shimoyama, Etsuko Aruga, Mika Baba, Koki Sumita, Satoru Iwase
BACKGROUND: Corticosteroids are often used to treat fatigue and anorexia, but occasionally produce delirium. Information on the predictors of delirium in corticosteroid-treated cancer patients remains limited. OBJECTIVE: To identify potential factors predicting the development of delirium in corticosteroid-treated cancer patients. DESIGN: An exploratory, multicenter, prospective, observational study. SETTING/SUBJECTS: Inclusion criteria for this study were patients who had metastatic or locally advanced cancer and a fatigue or anorexia intensity score of 4 or more on a 0-10 Numerical Rating Scale...
April 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28373469/nab-paclitaxel-and-gemcitabine-in-advanced-pancreatic-cancer-the-one-year-experience-of-the-national-cancer-institute-of-naples
#5
Alessandro Ottaiano, Monica Capozzi, Chiara DE Divitiis, Claudia VON Arx, Elena DI Girolamo, Guglielmo Nasti, Ernesta Cavalcanti, Fabiana Tatangelo, Giovanni Romano, Antonio Avallone, Salvatore Tafuto
BACKGROUND: Pancreas adenocarcinoma is the sixth cause of cancer-related death worldwide with an increasing mortality in the Western countries. Recently, the association between nab-paclitaxel (nab-P) and gemcitabine (GEM) has significantly improved progression-free and overall survival. PATIENTS AND METHODS: Patients affected by metastatic pancreas adenocarcinoma were treated at the Department of Abdominal Oncology of the National Cancer Institute of Naples from July 2015 to July 2016 with nab-P at 125 mg per square meter of body-surface area followed by GEM at 1,000 mg per square meter on days 1, 8 and 15 every 4 weeks...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28365172/segmental-yttrium-90-radioembolization-versus-segmental-chemoembolization-for-localized-hepatocellular-carcinoma-results-of-a-single-center-retrospective-propensity-score-matched-study
#6
Siddharth A Padia, Guy E Johnson, Kathryn J Horton, Christopher R Ingraham, Matthew J Kogut, Sharon Kwan, Sandeep Vaidya, Wayne L Monsky, James O Park, Renuka Bhattacharya, Daniel S Hippe, William P Harris
PURPOSE: To compare segmental radioembolization with segmental chemoembolization for localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. MATERIALS AND METHODS: In a single-center, retrospective study (2010-2015), 101 patients with 132 tumors underwent segmental radioembolization, and 77 patients with 103 tumors underwent segmental doxorubicin-based drug-eluting embolic or conventional chemoembolization. Patients receiving chemoembolization had worse performance status (Eastern Cooperative Oncology Group 0, 76% vs 56%; P = ...
March 29, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28356749/adrenalectomy-does-not-improve-survival-rates-of-patients-with-solitary-adrenal-metastasis-from-non-small-cell-lung-cancer
#7
Shao-Hong Huang, Qing-Lei Kong, Xue-Xia Chen, Jin-Yuan He, Jie Qin, Zhuang-Gui Chen
BACKGROUND AND PURPOSE: Several case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC). This study aimed to investigate whether NSCLC patients with solitary adrenal metastasis could gain a higher survival rate after adrenalectomy (ADX) when compared with those patients undergoing nonsurgical treatment, and to investigate the potential prognostic factors. PATIENTS AND METHODS: A total of 1,302 NSCLC inpatients' data from 2001 to 2015 were retrospectively reviewed to identify those with solitary adrenal metastasis...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28355079/ultrafast-charge-transfer-between-light-absorber-and-co3o4-water-oxidation-catalyst-across-molecular-wires-embedded-in-silica-membrane
#8
Eran Edri, Jason K Cooper, Ian D Sharp, Dirk M Guldi, Heinz Frei
The mechanism of visible light-induced hole transfer from a molecular light absorber, in the form of a free-base porphyrin, coupled to a Co3O4 nanoparticle catalyst for water oxidation by a molecular wire (p-oligo(phenylenevinylene) featuring three aryl units) is investigated by transient absorption spectroscopy. The wires are covalently anchored on the Co3O4 surface and embedded in a dense, yet ultrathin (2 nm), silica layer that separates light absorber and catalyst. The porphyrin is electrostatically adsorbed on the silica surface, and aqueous colloidal solutions of the core-shell particles are used for transient optical measurements...
April 6, 2017: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/28353038/a-scoring-system-to-guide-the-decision-for-a-new-systemic-treatment-after-at-least-two-lines-of-palliative-chemotherapy-for-metastatic-cancers-a-prospective-study
#9
Brice Chanez, François Bertucci, Marine Gilabert, Anne Madroszyk, Frédérique Rousseau, Delphine Perrot, Patrice Viens, Jean-Luc Raoul
PURPOSE: A four-parameter score has been identified as associated with overall survival (OS) in patients with advanced cancer with an estimated survival inferior to 6 months. Here, we tested its prognostic value for OS in patients who had received more than two lines of systemic therapy. METHODS: We prospectively enrolled patients with advanced cancer who were going to receive a third or more therapeutic line outside classical clinical guidelines. The four parameters (Eastern Cooperative Oncology Group performance status, number of metastatic sites, serum LDH, and serum albumin) were collected at baseline, allowing to calculate the score, which sorted the patients in three groups, A, B, and C (low, intermediate, and high score, respectively)...
March 28, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28330462/prospective-phase-ii-trial-of-everolimus-in-pik3ca-amplification-mutation-and-or-pten-loss-patients-with-advanced-solid-tumors-refractory-to-standard-therapy
#10
Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim
BACKGROUND: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538). METHODS: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day cycles). Treatment was continued until progression of the disease or intolerable toxicity was observed. Based on Simon's two-stage optimal design, 10 patients were treated with everolimus during the first stage...
March 23, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28293125/trajectory-of-chemotherapy-for-patients-with-egfr-wild-type-advanced-pulmonary-adenocarcinoma-a-single-institution-retrospective-study
#11
Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta
BACKGROUND: Pulmonary adenocarcinoma, recently benefited by new cytotoxic and molecularly targeted drugs, has been classified by driver mutations, such as EGFR mutations. The aim of this study was to research the proportions of patients treated with first- to third-line chemotherapy and to find influential factors for the introduction of chemotherapy and survival benefit from chemotherapy. MATERIALS AND METHODS: Data were collected retrospectively on patients who met the following criteria: adenocarcinoma, diagnosed between June 2007 and March 2015 at our hospital, stage IIIB or IV, and EGFR wild type...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28285682/pretreatment-neutrophil-to-lymphocyte-ratio-as-a-marker-of-outcomes-in-nivolumab-treated-patients-with-advanced-non-small-cell-lung-cancer
#12
Stephen J Bagley, Shawn Kothari, Charu Aggarwal, Joshua M Bauml, Evan W Alley, Tracey L Evans, John A Kosteva, Christine A Ciunci, Peter E Gabriel, Jeffrey C Thompson, Susan Stonehouse-Lee, Victoria E Sherry, Elizabeth Gilbert, Beth Eaby-Sandy, Faith Mutale, Gloria DiLullo, Roger B Cohen, Anil Vachani, Corey J Langer
OBJECTIVES: Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma treated with ipilimumab, a pretreatment neutrophil-to-lymphocyte ratio (NLR)<5 has been associated with improved survival. This retrospective cohort study aimed to determine whether the pretreatment NLR was associated with outcomes in NSCLC patients treated with nivolumab. METHODS: We reviewed the medical records of all patients with previously treated advanced NSCLC who received nivolumab between March 2015 and March 2016 outside of a clinical trial at the University of Pennsylvania...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28282611/phase-ib-dose-finding-study-of-abiraterone-acetate-plus-buparlisib-bkm120-or-dactolisib-bez235-in-patients-with-castration-resistant-prostate-cancer
#13
Christophe Massard, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean-Pascal Machiels, Alain Mita, Begona Mellado Gonzalez, Sabine Turri, Joan Maier, Denes Csonka, Arunava Chakravartty, Karim Fizazi
BACKGROUND: The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation in phosphatase and tensin homologue (PTEN)-deficient metastatic castration-resistant prostate cancer (CRPC) in preclinical models. This phase Ib study evaluated the pan-PI3K inhibitor buparlisib (BKM120) and the dual pan-PI3K/ mammalian target of rapamycin (mTOR) inhibitor dactolisib (BEZ235) in combination with abiraterone acetate (AA) in patients with CRPC...
May 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28267709/predicting-serious-complications-in-patients-with-cancer-and-pulmonary-embolism-using-decision-tree-modelling-the-epiphany-index
#14
A Carmona-Bayonas, P Jiménez-Fonseca, C Font, F Fenoy, R Otero, C Beato, J M Plasencia, M Biosca, M Sánchez, M Benegas, D Calvo-Temprano, D Varona, L Faez, I de la Haba, M Antonio, O Madridano, M P Solis, A Ramchandani, E Castañón, P J Marchena, M Martín, F Ayala de la Peña, V Vicente
BACKGROUND: Our objective was to develop a prognostic stratification tool that enables patients with cancer and pulmonary embolism (PE), whether incidental or symptomatic, to be classified according to the risk of serious complications within 15 days. METHODS: The sample comprised cases from a national registry of pulmonary thromboembolism in patients with cancer (1075 patients from 14 Spanish centres). Diagnosis was incidental in 53.5% of the events in this registry...
April 11, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28267060/determination-of-mild-moderate-and-severe-pain-interference-in-patients-with-cancer
#15
Qiuling Shi, Tito R Mendoza, Amylou C Dueck, Haijun Ma, Jeffrey Zhang, Yi Qian, Debajyoti Bhowmik, Charles S Cleeland
Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials...
March 4, 2017: Pain
https://www.readbyqxmd.com/read/28259489/association-between-frailty-and-readmission-within-one-year-after-gastrectomy-in-older-patients-with-gastric-cancer
#16
Yu-Ri Choe, Ju-Youn Joh, Yeon-Pyo Kim
OBJECTIVE: The incidence of gastric cancer in older people is increasing. Because older patients are at increased risk of postoperative complications and mortality, preoperative risk assessment in this population is important. This study explored whether preoperative assessment of frailty could be useful for predicting the postoperative outcome in patients with gastric cancer. MATERIALS AND METHODS: We investigated 223 patients (136 men and 87 women) over 65years of age who underwent gastric cancer surgery from April 2012 to March 2015 at a single institution in Korea...
March 1, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28222524/a-combination-of-resveratrol-and-curcumin-is-effective-against-aluminum-chloride-induced-neuroinflammation-in-rats
#17
Amira Zaky, Ahmad Bassiouny, Mahitab Farghaly, Bassma M El-Sabaa
BACKGROUND: Experimental studies have demonstrated that aluminum is an environmental toxin that induces neuroinflammation and the development of Alzheimer's disease. OBJECTIVE: In this report, we investigated the beneficial effect of a combination of resveratrol and curcumin to reduce aluminum-induced neuroinflammation. METHOD: We employed both an in vivo model of aluminum-induced neuroinflammation and an in vitro aluminum stimulated cultured PC-12 cells...
February 7, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28212999/meta-analysis-examining-impact-of-age-on-overall-survival-with-pemetrexed-for-the-treatment-of-advanced-non-squamous-non-small-cell-lung-cancer
#18
Luis G Paz-Ares, Annamaria Zimmermann, Tudor Ciuleanu, Paul A Bunn, Belen San Antonio, Jonathan Denne, Nancy Iturria, William John, Giorgio V Scagliotti
OBJECTIVE: In clinical practice, elderly patients are often undertreated relative to younger patients. This meta-analysis was designed to determine whether older patients with non-squamous non-small cell lung cancer (NSCLC) could derive an overall survival (OS) benefit from pemetrexed treatment comparable to that experienced by younger patients in the first-line, second-line, or maintenance settings. METHODS: Data from 2671 patients with non-squamous NSCLC participating in four pemetrexed phase III studies were included in a meta-analysis using a random-effects model...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#19
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28160352/outcomes-of-children-adolescents-and-young-adults-following-allogeneic-stem-cell-transplantation-for-secondary-acute-myeloid-leukemia-and-myelodysplastic-syndromes-the-md-anderson-cancer-center-experience
#20
Ossama M Maher, Jorge Galvez Silva, Jimin Wu, Diane Liu, Laurence J N Cooper, Nidale Tarek, Laura Worth, Dean A Lee, Demetrios Petropoulos, Anna R K Franklin, Patrick Zweidler-Mckay, Robert J Wells, Gabriela Rondon, Richard E Champlin, Priti Tewari
We conducted a retrospective analysis of outcomes for children and young adults with sAML/sMDS who underwent HSCT at our institution. Thirty-two patients (median age 20 years) with sAML (n=24) and sMDS (n=8) received HSCT between 1990 and 2013. The median time from sAML/sMDS diagnosis to HSCT was 4.1 months (range: 1.2-27.2 months). The transplant regimens were primarily busulfan based (n=19). BM was the primary donor source (n=15). Eleven recipients were transplanted with residual disease. At a median follow-up of 62...
May 2017: Pediatric Transplantation
keyword
keyword
115948
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"